Nivelles, Belgium / Chandigarh — 19 Junes 26 — Quantoom Biosciences – a full-stack RNA partner providing turnkey solutions for mRNA- and saRNA-based vaccines and therapeutics – today announce a strategic partnership with Enparis Bio (India) to accelerate access of its N-Force platform to India’s vaccine, biotech and life-science sectors.
Under this agreement, Enparis Bio will support Quantoom’s business development efforts in India and act as its trusted scientific/knowledge partner, supporting customer engagement, on-the-ground technical training, and demonstration activities. A locally established innovation hub will open the door for India’s researchers and manufacturers to experience next-generation RNA production capabilities firsthand.
A local hub to support India’s growing RNA ambitions
India is a global hub for vaccine development and biomanufacturing, with a rising focus on mRNA-based vaccines and therapeutics. Through this collaboration, Indian scientists and biotech innovators will gain in-country access to a turnkey RNA production solution that integrates process, equipment, optimized reagent mixes, and technical support into a single workflow, supported by certified local expertise.
The partnership also brings locally delivered training and certification on Quantoom’s N-Force technologies, shortening the path from first contact to operational adoption. As with Quantoom’s other regional collaborations, the Ntensify platform offers a continuous path from microgram-level experiments to multi-gram production, providing Indian teams with a practical route from early research through process development to commercial manufacturing readiness.
Quotes
José Castillo, CEO of Quantoom Biosciences, said: “India is a strategic market for the future of RNA medicines, and partnering with Enparis Bio gives us a trusted local presence to engage with the country’s vibrant scientific and biomanufacturing community. Together, we aim to make advanced RNA production technologies more accessible to Indian innovators.”
Sudhir Sharma and Radhika Sharma, Managing Directors of Enparis Bio, said: “Our long association with Quantoom has been built on mutual trust and a shared vision for advancing mRNA technologies by combining scientific rigor with a commitment to building local capacity and capability. Extending this collaboration into India will empower researchers and manufacturers with the tools, training, and support needed to accelerate adoption of RNA platforms.”
About Quantoom Biosciences
Quantoom Biosciences is a full-stack RNA partner providing turnkey solutions for mRNA- and saRNA-based vaccines and therapeutics, covering the full workflow from sequence design to RNA production and LNP formulation. It’s mission is to provide any player of the life-science biotech sector with tools to rapidly translate their science into life-changing RNA medicine.
Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization. For more information, visit www.quantoom.com.
About Enparis Bio (India)
Enparis Bio Private Limited is an India-based biotechnology company dedicated to translational innovations and ecosystem building in Precision Medicine. Enparis Bio focuses on modular, population-aware platforms for mRNA therapeutics, cancer vaccines, and precision nutrition. Headquartered in the Chandigarh Tricity, the company bridges cutting-edge science with practical, scalable solutions that strengthen India’s biotech capacity.
Media contact
Nicolas DANTINNE – Marcom manager @ Quantoom – n.dantinne@quantoom.com
Sudhir SHARMA – CEO @ Enparis Bio Private Limited – sudhir@enparisbio.com
